Observational, Single Arm, Prospective Study to Evaluate the Effectiveness of Legalon in Addition to Diet and Exercise in Reducing Plasma Levels of Liver Enzymes
Latest Information Update: 04 May 2023
At a glance
- Drugs Silibinin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Mylan
- 26 Apr 2023 Status changed from not yet recruiting to recruiting.
- 26 Apr 2022 Planned initiation date changed from 1 Apr 2022 to 1 May 2022.
- 04 Mar 2022 Planned initiation date changed from 28 Feb 2022 to 1 Apr 2022.